Plain-English translation of NCT05312671 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding a medication called to standard chemotherapy, followed by surgical removal of the bladder, works better than chemotherapy alone for people with a rare, aggressive form of bladder cancer called small cell neuroendocrine carcinoma. is an immunotherapy — a type of drug that helps your immune system fight cancer cells. All participants will receive the medication combined with two chemotherapy drugs, have surgery to remove their bladder, and then continue taking the medication for up to one year.
Small cell neuroendocrine bladder cancer is a rare but very aggressive cancer with poor outcomes using standard treatment alone. This trial exists to see whether adding this medication to help boost the immune system against cancer can improve survival and outcomes for patients with this difficult-to-treat disease.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive four rounds of intravenous chemotherapy and immunotherapy, with each round spaced three weeks apart. During this time, you'll have regular blood tests and scans to monitor how you're responding. After four rounds, you'll undergo surgery to remove your bladder. Following surgery, you'll continue receiving the immunotherapy medication by IV infusion every three weeks for up to one year, with ongoing monitoring visits and scans to check for side effects and how well the treatment is working.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States